LifeStance Health Group, Inc. $LFST Holdings Raised by Loomis Sayles & Co. L P

Loomis Sayles & Co. L P raised its stake in shares of LifeStance Health Group, Inc. (NASDAQ:LFST) by 4.5% in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 2,343,028 shares of the company’s stock after buying an additional 100,657 shares during the period. Loomis Sayles & Co. L P’s holdings in LifeStance Health Group were worth $12,113,000 as of its most recent SEC filing.

Other hedge funds have also modified their holdings of the company. Jacobs Levy Equity Management Inc. acquired a new position in LifeStance Health Group in the first quarter worth approximately $7,932,000. Adage Capital Partners GP L.L.C. increased its stake in shares of LifeStance Health Group by 43.8% during the 1st quarter. Adage Capital Partners GP L.L.C. now owns 230,000 shares of the company’s stock worth $1,532,000 after purchasing an additional 70,000 shares during the last quarter. TD Asset Management Inc bought a new position in shares of LifeStance Health Group during the 2nd quarter valued at $780,000. Nuveen LLC acquired a new stake in shares of LifeStance Health Group in the 1st quarter valued at $6,928,000. Finally, Los Angeles Capital Management LLC bought a new stake in LifeStance Health Group in the second quarter worth $219,000. 85.50% of the stock is owned by institutional investors and hedge funds.

LifeStance Health Group Stock Down 0.6%

Shares of LFST opened at $6.52 on Monday. The company has a debt-to-equity ratio of 0.18, a quick ratio of 1.58 and a current ratio of 1.58. The company has a 50-day simple moving average of $5.62 and a 200-day simple moving average of $5.28. LifeStance Health Group, Inc. has a 52 week low of $3.74 and a 52 week high of $8.30. The firm has a market capitalization of $2.54 billion, a P/E ratio of -217.33 and a beta of 1.12.

LifeStance Health Group (NASDAQ:LFST) last issued its quarterly earnings results on Thursday, November 6th. The company reported $0.02 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.01) by $0.03. LifeStance Health Group had a negative return on equity of 0.62% and a negative net margin of 0.67%.The firm had revenue of $363.81 million for the quarter, compared to analyst estimates of $355.06 million. During the same period in the previous year, the company posted ($0.02) earnings per share. The company’s quarterly revenue was up 16.3% compared to the same quarter last year. LifeStance Health Group has set its Q4 2025 guidance at EPS. FY 2025 guidance at EPS. On average, equities research analysts expect that LifeStance Health Group, Inc. will post -0.18 earnings per share for the current year.

Insiders Place Their Bets

In other LifeStance Health Group news, insider Lisa K. Miller sold 57,240 shares of the business’s stock in a transaction on Friday, November 21st. The shares were sold at an average price of $6.43, for a total value of $368,053.20. Following the sale, the insider owned 261,292 shares of the company’s stock, valued at $1,680,107.56. The trade was a 17.97% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. 6.60% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on LFST. Wall Street Zen cut LifeStance Health Group from a “buy” rating to a “hold” rating in a research report on Saturday, October 11th. Weiss Ratings restated a “sell (d-)” rating on shares of LifeStance Health Group in a report on Tuesday, November 25th. BMO Capital Markets started coverage on LifeStance Health Group in a research report on Thursday, November 13th. They set an “outperform” rating and a $8.00 target price for the company. BTIG Research lifted their price target on shares of LifeStance Health Group from $8.00 to $9.00 and gave the company a “buy” rating in a research report on Thursday, November 6th. Finally, Zacks Research downgraded shares of LifeStance Health Group from a “strong-buy” rating to a “hold” rating in a report on Wednesday, November 5th. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $9.00.

About LifeStance Health Group

LifeStance Health Group, Inc, through its subsidiaries, provides outpatient mental health services to children, adolescents, adults, and geriatrics in the United States. The company offers patients a suite of mental health services, including psychiatric evaluations and treatment, psychological, and neuropsychological testing, as well as individual, family, and group therapy.